Mass Tort brief
Insurers Face Class Liability as Teva Battles US MDLs
Israeli courts advance landmark auto and delayed-claim settlements while Teva defends sprawling antitrust and device injury dockets in US federal courts.
Mass Tort
Five top insurers agreed to pay ₪310M over late claim payments — ending a decade-long industry practice of pocketing statutory interest.
BackgroundUnder Section 28(a) of Israel's Insurance Contract Law, insurance carriers are legally obligated to add statutory interest and inflation linkage to payouts delayed past 30 days. Policyholders filed class actions alleging that insurers systematically withheld these mandatory adjustments to boost operational investment earnings.
- The comprehensive settlement covers Harel, Clal, The Phoenix, Migdal, and Ayalon following more than a decade of contentious litigation in Tel Aviv District Court.
- The Phoenix alone will pay out ₪74 million to affected policyholders, while Migdal and Harel absorb comparable payouts covering delayed property and life claims.
- Carriers agreed to implement automated compliance software monitored directly by the Capital Market, Insurance, and Savings Authority to prevent future calculation errors.
- The resolution represents one of the largest consumer financial class action payouts in Israeli legal history, establishing strict timelines for future claim payouts.
Mass Tort
With secondary generic drugmakers settling out, Teva stands isolated before federal juries — facing antitrust damages that could rival its opioid liabilities.
BackgroundState attorneys general filed antitrust lawsuits alleging that major generic drugmakers engaged in systemic price-fixing across hundreds of essential generic medications. Smaller manufacturers settled their exposure for tens of millions, leaving Teva as the central target facing federal antitrust trials.
- The court approved a $96.5 million consumer distribution framework funded by settlements with secondary drugmakers, accelerating restitution for retail prescription buyers.
- State prosecutors confirmed that primary antitrust damages claims remain focused on Teva and former corporate executives who directed generic pricing strategies.
- The legal exposure coincides with Teva's ongoing multi-year installment payments resolving nationwide American opioid liability agreements, straining free cash flow.
- Teva has consistently denied allegations of systemic price-fixing and continues to prepare extensive market competition defenses for upcoming federal trials in Hartford.
Mass Tort
Menora faces a certified class action for inflating claim records — an order that threatens insurers using hidden accounting adjustments to hike premiums.
BackgroundIsraeli auto insurers calculate future customer premiums based on a driver's prior three-year claim history under guidelines set by the Capital Market Authority. When a claimant crosses specific claim cost thresholds, insurers are legally permitted to raise annual policy premiums or deny comprehensive coverage.
- The court found that Menora systematically added third-party operational legal fees into policyholders' claim totals without regulatory authorization, artificially inflating individual loss histories.
- The accounting inflation pushed policyholder claim sums past the 35% premium reporting threshold, triggering unlawful premium increases for thousands of drivers.
- The judge certified claims under breach of statutory duty, negligence, and unjust enrichment, covering comprehensive and third-party vehicle policies issued between 2014 and 2021.
- The certified suit seeks full restitution of inflated premium charges alongside ₪1,000 per class member in non-pecuniary emotional distress compensation.
Mass Tort
Mounting US blindness lawsuits over GLP-1 drugs are forcing Israeli health funds to rewrite consent forms — tightening prescription safeguards before local product liability claims mount.
BackgroundGLP-1 receptor agonists like semaglutide and tirzepatide are widely prescribed across Israel for type 2 diabetes management and clinical weight loss. NAION is a severe medical condition caused by compromised blood flow to the optic nerve head, leading to sudden, irreversible blindness.
- The US multidistrict litigation panel consolidated 216 NAION blindness cases alongside 4,022 parallel suits alleging severe gastrointestinal injuries like stomach paralysis.
- The FDA formally designated NAION as an active safety signal, evaluating whether to mandate prominent black-box warnings on commercial drug packaging.
- Parallel consumer product liability petitions filed in Israel's Lod District Court are forcing health funds to review off-label weight loss prescription rules.
- Israeli HMO clinical directors are updating patient consent forms to explicitly document rare ophthalmological risks before prescribing GLP-1 treatments to new patients.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
